The new technology route of Ai Mei vaccines has two major heavyweight vaccine products that have received clinical approval.

ShangHai Securities NewsDec 20 22:00

AIM Vaccine For Tetanus Gets NMPA's Nod; Shares Rise 5%

MT NewswiresDec 20 13:46

The Aimee vaccine / Baked Biological Type II Herpes Simplex Virus mRNA vaccine has been approved for clinical trials.

China Internet FinanceDec 20 12:42

Aimer vaccine (06660.HK): The second-generation high-potency adsorbed tetanus vaccine has obtained clinical trial approval.

On December 19, Gelonghui announced that Aime Vaccine (06660.HK) has recently received the "Notice of Drug Clinical Trial Approval" from the National Medical Products Administration for the group's second-generation high-titer adsorbed tetanus vaccine, marking a new phase in the vaccine's development. Tetanus is an extremely serious potentially fatal disease, and currently, vaccination against tetanus is the most cost-effective measure for its prevention. In addition, the group is actively promoting the research and development of multi-component vaccines such as the adsorbed acellular DTP-HIB combined vaccine (referred to as the "quad vaccine") and the pentavalent vaccine. Among them, the quad vaccine is used to prevent whooping cough and diphtheria.

Gelonghui FinanceDec 19 21:27

AIM Vaccine Advances With New Influenza Vaccine Trial

TipRanksDec 19 18:37

Aimei Vaccine (06660): New technological route for suspended culture of quadrivalent MDCK cell influenza vaccine has obtained clinical trial approval.

Aimee Vaccine (06660) announced that the group’s new technological route has developed a suspended culture quadrivalent MDCK cell influenza vaccine, which has already...

Zhitong FinanceDec 19 18:12